

OZANIMOD capsules (Zeposia® ▼) for ulcerative colitis

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of OZANIMOD capsules (Zeposia® ▼) for ulcerative colitis.

GREY

Ozanimod has been granted a license extension and is now indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.^[1]

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, treatment of ulcerative colitis should continue to follow national guidance and local formulary choices:

- > NICE Guideline NG130: [Ulcerative colitis: management](#) (03 May 2019).
- > Pan Mersey APC pathway: [Inflammatory Bowel Disease High Cost Drugs Treatment Pathway for Adults](#) (last updated 02 July 2021).
- > Pan Mersey APC Formulary: [Gastrointestinal system](#)

References

1. Bristol Myers Squibb Pharmaceuticals limited. Summary of Product Characteristics; [Zeposia 0.23 mg hard capsules](#), 03 February 2022. Accessed online 13 April 2022.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.